Also trades as: 0SZI.L (LSE) · $vol 0M
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
1W: -14.2%
1M: -46.6%
3M: -31.9%
YTD: -22.1%
1Y: -53.0%
3Y: -3.5%
5Y: -80.3%
$6.13
-0.21 (-3.31%)
Weekly Expected Move ±12.2%
$5
$5
$6
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$113.6M
52W Range6.06-20.56
Volume834,833
Avg Volume715,774
Beta2.64
Dividend—
Analyst Ratings
Company Info
CEOYuval Cohen
Employees36
SectorHealthcare
IndustryBiotechnology
IPO Date2014-10-27
Websitecorbuspharma.com
500 River Ridge Drive
Norwood, MA 02062
US
Norwood, MA 02062
US
617 963 0100
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Latest News
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Corbus Pharmaceuticals GAAP EPS of -$1.81
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
CRBP: I think this is one of the most overlooked biotech catalysts of 2026
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ben Yong | S-Sale | 2,000 | $7.84 | 2026-09-14 |
| Nicacio Leonardo Via | A-Award | 58,333 | — | 2026-08-16 |
| Nicacio Leonardo Via | A-Award | 191,676 | $10.09 | 2026-08-16 |
| Saxena Nishant C | P-Purchase | 2,600 | $9.63 | 2026-08-11 |
| Cohen Yuval | S-Sale | 17,000 | $10.08 | 2026-08-07 |